Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)

NCT06117150 | Active Not Recruiting Phase 1

• 1 other identifier: CP-008
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 2

Brief Summary

To demonstrate acceptable short term safety rates of the Drug-eluting Coronary Spur Stent System as a primary treatment for coronary in-stent restenosis.

Conditions

In-stent Restenosis

Outcome Measures

Primary Outcomes (1)

• Treatment of the target lesion with the Drug-Eluting Coronary Spur Stent System without occurrence of in-hospital Major Adverse Cardiac Events (MACE).

  MACE is defined as All-cause death, Myocardial Infarction (MI), any clinically-driven target lesion revascularization (TLR).

  From time of enrollment procedure through time of post-procedure discharge

Study Arms (1)

Drug-eluting Coronary Spur StEnt System

EXPERIMENTAL

All subjects enrolled will receive the Drug-eluting Coronary Spur Stent System.

Device: Drug-eluting Coronary Spur Stent System

Interventions

Drug-eluting Coronary Spur Stent System DEVICE

All subjects enrolled will be treated with the Drug-eluting Coronary Spur Stent System.

Drug-eluting Coronary Spur StEnt System

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject willing and able to provide informed consent and able to comply with the study protocol and follow up. Subjects who are unable to sign due to a physical limitation may have a legal guardian or legally authorized representative (LAR) sign on their behalf.
• Life expectancy greater than 2 years in the investigator's opinion.
• Subject is greater than 18 years of age.
• Female subjects of childbearing potential have a negative pregnancy test ≤ 7 days before the procedure.
• Endovascular treatment is able to be conducted under non-emergent conditions.
• Documented stable or unstable angina including non-ST-elevation MI, functional testing demonstrating ischemia, and/or clinical symptoms that in the opinion of the investigator are not amenable to conservative medical therapy and require endovascular intervention.
• Subject is eligible for dual antiplatelet therapy (DAPT) treatment with aspirin plus P2Y12 inhibitor.
• Target vessel is of appropriate size and diameter to be treated with the Coronary Spur Stent.
• Target lesion is within a previously placed Bare Metal Stent (BMS) or Drug-eluting Stent (DES) and does not extend further than 5mm beyond either the proximal or distal edge of the stent.
• In-stent restenosis of \>50% diameter by angiography.
• Up to two (2) non-target lesions in non-target vessels may be treated, but successful percutaneous coronary intervention (PCI) of the non-target lesions must be completed before treatment of the target lesion. Successful treatment of a non-target lesion is defined as a residual stenosis of ≤ 30% in 2 near-orthogonal projections with Thrombolysis in Myocardial Infarction (TIMI) 3 flow, as visually assessed by the physician, without the occurrence of prolonged chest pain or ECG changes consistent with MI.
• Successful pre-dilatation of the target lesion, defined as non-compromised flow or presence of thrombus.

You may not qualify if:

• Subject unwilling or unlikely to comply with the one-year duration of the study as in the opinion of the investigator.
• Subject is pregnant, breast-feeding, or is a woman of childbearing potential who is not using appropriate contraceptives.
• Subject has an active systemic infection that is not controlled at the time of the procedure, including septicemia or bacteremia.
• Stroke within 90 days of the index procedure.
• Documented left ventricular ejection fraction (LVEF) \<35% by echocardiography.
• In-stent restenosis occurring in less than 90 days prior to the index procedure.
• Impaired renal function (eGFR less than or equal to 25 mL/min) within 30 days of procedure or end stage renal disease on dialysis.
• \. History of active peptic ulcer or gastrointestinal bleeding within prior 6 months or other inability to comply with recommended duration of DAPT.
• \. Known allergies or sensitivities to heparin, antiplatelet drugs, other anticoagulant therapies which could not be substituted, drug balloon coatings and their excipients, including, but not limited to, paclitaxel, sirolimus, or zotarolimus, or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure.
• \. The subject is currently enrolled in another investigational device or drug trial that interferes with the study endpoints.
• \. Known allergy to nitinol or nickel.
• \. Any expected elective surgical procedure that would necessitate interruption of DAPT through the 12-month visit.
• \. Planned use of atherectomy (rotational, orbital, or laser) device, cutting or scoring balloon.
• \. Severe hepatic dysfunction (3 times normal reference values).
• \. Planned treatment of additional lesions in target vessel or \> two (2) non-target lesions within non-target vessels during index procedure.

Sponsors & Collaborators

• ReFlow Medical, Inc.: lead

Study Sites (2)

Auckland City Hospital Te Toka Tumai

Auckland, Grafton, 1142, New Zealand

Location

Wellington Hospital | Capital, Coast and Hutt Valley

Wellington, Wellington Region, 6023, New Zealand

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 28, 2023
• First Posted: November 3, 2023
• Study Start: June 9, 2024
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: August 8, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

NZ (2)